A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer

Trial Profile

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 May 2017

At a glance

  • Drugs MVI 118 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Mar 2017 According to a Madison Vaccine media release, this trial is expanding to a third clinical site - The University of Washington-Seattle.
    • 27 Oct 2016 According to a Madison Vaccines media release, a new trial site has been added at Rutgers Cancer Institute of New Jersey, and the principal investigator is Anna Ferrari, MD.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top